Estrogen and selective estrogen receptor modulators (SERMs) for the treatment of acromegaly: A meta-analysis of published observational studies

Pituitary

Volumn 17, Issue 3, 2014, Pages 284-295

  Stone, Jennifer C ^a   Clark, Justin ^a   Cuneo, Ross ^b   Russell, Anthony W ^a,b   Doi, Suhail A R ^a,b  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b PRINCESS ALEXANDRA HOSPITAL   (Australia)

Author keywords

Acromegaly; Estrogen; IGF 1; Meta analysis; SERM

Indexed keywords

CYPROTERONE ACETATE; DESOGESTREL; DOPAMINE RECEPTOR STIMULATING AGENT; ESTRADIOL; ESTROGEN; ETHINYLESTRADIOL; LEVONORGESTREL; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; SOMATOMEDIN C; SOMATOSTATIN RECEPTOR; TAMOXIFEN;

ACROMEGALY; ARTICLE; DRUG COST; DRUG EFFICACY; DRUG RESPONSE; ESTROGEN THERAPY; HUMAN; META ANALYSIS; NEUROSURGERY; OBSERVATIONAL STUDY; PRIORITY JOURNAL; SYSTEMATIC REVIEW; TREATMENT DURATION; FEMALE; MALE; TREATMENT OUTCOME;

ACROMEGALY; ESTROGENS; FEMALE; HUMANS; MALE; OBSERVATIONAL STUDY AS TOPIC; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TREATMENT OUTCOME;

EID: 84905709106     PISSN: 1386341X     EISSN: 15737403     Source Type: Journal    
DOI: 10.1007/s11102-013-0504-2     Document Type: Article

References (72)

1. Katznelson L, Atkinson JL, Cook DM, Ezzat SZ, Hamrahian AH, Miller KK (2011) American Association of Clinical Endocrinologists medical guidelines for clinical practice for the diagnosis and treatment of acromegaly-2011 update. Endocr Pract 17(Suppl 4):1-44
2. Dekkers OM, Biermasz NR, Pereira AM, Romijn JA, Vandenbroucke JP (2008) Mortality in acromegaly: a metaanalysis. J Clin Endocrinol metab 93(1):61-67
3. Mestron A, Webb SM, Astorga R, Benito P, Catala M, Gaztambide S, Gomez JM, Halperin I, Lucas-Morante T, Moreno B, Obiols G, de Pablos P, Paramo C, Pico A, Torres E, Varela C, Vazquez JA, Zamora J, Albareda M, Gilabert M (2004) Epidemiology, clinical characteristics, outcome, morbidity and mortality in acromegaly based on the Spanish Acromegaly Registry (Registro Espanol de Acromegalia, REA). Eur J Endocrinol 151(4):439-446
4. Melmed S, Casanueva F, Cavagnini F, Chanson P, Frohman LA, Gaillard R, Ghigo E, Ho K, Jaquet P, Kleinberg D, Lamberts S, Laws E, Lombardi G, Sheppard MC, Thorner M, Vance ML, Wass JA, Giustina A (2005) Consensus statement: medical management of acromegaly. Eur J Endocrinol 153(6):737-740 (Pubitemid 43020222)
5. Holdaway IM, Bolland MJ, Gamble GD (2008) A meta-analysis of the effect of lowering serum levels of GH and IGF-I on mortality in acromegaly. Eur J Endocrinol 159(2):89-95
6. Swearingen B, Barker FG 2nd, Katznelson L, Biller BM, Grinspoon S, Klibanski A, Moayeri N, Black PM, Zervas NT (1998) Long-term mortality after transsphenoidal surgery and adjunctive therapy for acromegaly. J clin endocrinol metab 83(10):3419-3426 (Pubitemid 28500866)
7. Anagnostis P, Efstathiadou ZA, Polyzos SA, Adamidou F, Slavakis A, Sapranidis M, Litsas ID, Katergari S, Selalmatzidou D, Kita M (2011) Acromegaly: presentation, morbidity and treatment outcomes at a single centre. Int J Clin Pract 65(8):896-902
8. Fukuda I, Hizuka N, Murakami Y, Itoh E, Yasumoto K, Sata A, Takano K (2001) Clinical features and therapeutic outcomes of 65 patients with acromegaly at Tokyo Women's Medical University. Intern Med 40(10):987-992 (Pubitemid 33041137)
9. Minniti G, Jaffrain-Rea ML, Esposito V, Santoro A, Tamburrano G, Cantore G (2003) Evolving criteria for post-operative biochemical remission of acromegaly: can we achieve a definitive cure? An audit of surgical results on a large series and a review of the literature. Endocr Relat Cancer 10(4):611-619 (Pubitemid 38094895)
10. Nomikos P, Buchfelder M, Fahlbusch R (2005) The outcome of surgery in 668 patients with acromegaly using current criteria of biochemical 'cure'. Eur J Endocrinol 152(3):379-387 (Pubitemid 40439490)
11. Reid TJ, Post KD, Bruce JN, Nabi Kanibir M, Reyes-Vidal CM, Freda PU (2010) Features at diagnosis of 324 patients with acromegaly did not change from 1981 to 2006: acromegaly remains under-recognized and under-diagnosed. Clin Endocrinol (Oxf) 72(2):203-208
12. Trepp R, Stettler C, Zwahlen M, Seiler R, Diem P, Christ ER (2005) Treatment outcomes and mortality of 94 patients with acromegaly. Acta Neurochir (Wien) 147(3):243-251 discussion 250-241
13. Melmed S, Colao A, Barkan A, Molitch M, Grossman AB, Kleinberg D, Clemmons D, Chanson P, Laws E, Schlechte J, Vance ML, Ho K, Giustina A (2009) Acromegaly Consensus, G.: guidelines for acromegaly management: an update. J Clin Endocrinol Metab 94(5):1509-1517
14. Melmed S (1993) Medical management of acromegaly-what and when? Acta Endocrinol (Copenh) 129(Suppl 1):13-17
15. Lacy CF, Armstrong LL, Goldman MP, Lance LL (2013) Drug information handbook, 22nd edn. Lexi-Comp, Inc., Hudson
16. Abs R, Verhelst J, Maiter D, Van Acker K, Nobels F, Coolens J-L, Mahler C, Beckers A (1998) Cabergoline in the treatment of acromegaly: a study in 64 patients. J Clin Endocrinol Metab 83(2):374-378 (Pubitemid 28496509)
17. Colao A, Ferone D, Marzullo P, Di Sarno A, Cerbone G, Sarnacchiaro F, Cirillo S, Merola B, Lombardi G (1997) Effect of different dopaminergic agents in the treatment of acromegaly. J Clin Endocrinol Metab 82(2):518-523 (Pubitemid 27068622)
18. Cozzi R, Attanasio R, Barausse M, Dallabonzana D, Orlandi P, Da Re N, Branca V, Oppizzi G, Gelli D (1998) Cabergoline in acromegaly: a renewed role for dopamine agonist treatment? Eur J Endocrinol 139(5):516-521 (Pubitemid 28539706)
19. Jackson SNJ, Fowler J, Howlett TA (1997) Cabergoline treatment of acromegaly: a preliminary dose finding study. Clin Endocrinol 46(6):745-749 (Pubitemid 27304460)
20. Mercado M, Borges F, Bouterfa H, Chang T.-C, Chervin A, Farrall AJ, Patocs A, Petersenn S, Podoba J, Safari M, Wardlaw J, on behalf of the, S. M. S. B. S. G. (2007) A prospective, multicentre study to investigate the efficacy, safety and tolerability of octreotide LAR® (long-acting repeatable octreotide) in the primary therapy of patients with acromegaly. Clin Endocrinol 66(6):859-868 (Pubitemid 47024274)
21. Caron P, Beckers A, Cullen DR, Goth MI, Gutt B, Laurberg P, Pico AM, Valimaki M, Zgliczynski W (2002) Efficacy of the new long-acting formulation of lanreotide (Lanreotide Autogel) in the management of acromegaly. J Clin Endocrinol Metab 87(1):99-104 (Pubitemid 34084677)
22. Caron P, Morange-Ramos I, Cogne M, Jaquet P (1997) Three year follow-up of acromegalic patients treated with intramuscular slow-release lanreotide. J Clin Endocrinol Metab 82(1):18-22 (Pubitemid 27021263)
23. Maiza JC, Vezzosi D, Matta M, Donadille F, Loubes-Lacroix F, Cournot M, Bennet A, Caron P (2007) Long-term (up to 18 years) effects on GH/IGF-1 hypersecretion and tumour size of primary somatostatin analogue (SSTa) therapy in patients with GH-secreting pituitary adenoma responsive to SSTa. Clin Endocrinol 67(2):282-289 (Pubitemid 47076308)
24. Chanson P, Boerlin V, Ajzenberg C, Bachelot Y, Benito P, Bringer J, Caron P, Charbonnel B, Cortet C, Delemer B, Escobar-Jiménez F, Foubert L, Gaztambide S, Jockenhoevel F, Kuhn JM, Leclere J, Lorcy Y, Perlemuter L, Prestele H, Roger P, Rohmer V, Santen R, Sassolas G, Scherbaum WA, Schopohl J, Torres E, Varela C, Villamil F, Webb SM (2000) Comparison of octreotide acetate LAR and lanreotide SR in patients with acromegaly. Clin Endocrinol 53(5):577-586
25. van der Lely AJ, Hutson RK, Trainer PJ, Besser GM, Barkan AL, Katznelson L, Klibanski A, Herman-Bonert V, Melmed S, Vance ML, Freda PU, Stewart PM, Friend KE, Clemmons DR, Johannsson G, Stavrou S, Cook DM, Phillips LS, Strasburger CJ, Hacker S, Zib KA, Davis RJ, Scarlett JA, Thorner MO (2001) Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist. The Lancet 358(9295):1754-1759 (Pubitemid 33152999)
26. van der Lely AJ, Biller BM, Brue T, Buchfelder M, Ghigo E, Gomez R, Hey-Hadavi J, Lundgren F, Rajicic N, Strasburger CJ, Webb SM, Koltowska-Haggstrom M (2012) Long-term safety of pegvisomant in patients with acromegaly: comprehensive review of 1,288 subjects in ACROSTUDY. J Clin Endocrinol Metab 97(5):1589-1597
27. Moore DJ, Adi Y, Connock MJ, Bayliss S (2009) Clinical effectiveness and cost-effectiveness of pegvisomant for the treatment of acromegaly: a systematic review and economic evaluation. BMC Endocr Disord 9:20
28. Cozzi R, Attanasio R, Oppizzi G, Orlandi P, Giustina A, Lodrini S, Da Re N, Dallabonzana D (1997) Effects of tamoxifen on GH and IGF-I levels in acromegaly. J Endocrinol Invest 20(8):445-451 (Pubitemid 27483069)
29. Cozzi R, Barausse M, Lodrini S, Lasio G, Attanasio R (2003) Estroprogestinic pill normalizes IGF-I levels in acromegalic women. J Endocrinol Invest 26(4):347-352 (Pubitemid 36763696)
30. Attanasio R, Barausse M, Cozzi R (2003) Raloxifene lowers IGFI levels in acromegalic women. Eur J Endocrinol 148(4):443-448 (Pubitemid 36527415)
31. Dimaraki E, Symons K, Barkan A (2004) Raloxifene decreases serum IGF-I in male patients with active acromegaly. Eur J Endocrinol 150(4):481-487 (Pubitemid 38584698)
32. Shimon I, Barkan A (2012) Estrogen treatment for acromegaly. Pituitary 15(4):601-607
33. Vallette S, Serri O (2010) Oral estroprogestin: an alternative low cost therapy for women with postoperative persistent acromegaly? Pituitary 13(4):311-314
34. Clemmons DR, Underwood LE, Ridgway EC, Kliman B, Kjellberg RN, Van Wyk JJ (1980) Estradiol treatment of acromegaly. Reduction of immunoreactive somatomedin-C and improvement in metabolic status. Am J Med 69(4):571-575 (Pubitemid 10018713)
35. Duschek EJ, Gooren LJ, Netelenbos C (2005) Comparison of effects of the rise in serum testosterone by raloxifene and oral testosterone on serum insulin-like growth factor-1 and insulinlike growth factor binding protein-3. Maturitas 51(3):286-293 (Pubitemid 40835949)
36. Birzniece V, Sutanto S, Ho KK (2012) Gender difference in the neuroendocrine regulation of growth hormone axis by selective estrogen receptor modulators. J Clin Endocrinol Metab 97(4):E521-E527
37. Duschek EJ, Valk-de Roo GW, Gooren LJ, Netelenbos C (2004) Effects of conjugated equine estrogen vs. raloxifene on serum insulin-like growth factor-i and insulin-like growth factor binding protein-3: a 2-year, double-blind, placebo-controlled study. Fertil Steril 82(2):384-390 (Pubitemid 39092039)
38. Weissberger AJ, Ho KK, Lazarus L (1991) Contrasting effects of oral and transdermal routes of estrogen replacement therapy on 24-hour growth hormone (GH) secretion, insulin-like growth factor I, and GH-binding protein in postmenopausal women. J Clin Endocrinol Metab 72(2):374-381 (Pubitemid 21921702)
39. Helle SI, Holly JM, Tally M, Hall K, Vander Stappen J, Lonning PE (1996) Influence of treatment with tamoxifen and change in tumor burden on the IGF-system in breast cancer patients. Int J Cancer 69(4):335-339
40. da Silva BB, Moita DS, Pires CG, Sousa-Junior. EC, dos Santos AR, Lopes-Costa PV (2007) Evaluation of insulin-like growth factor-I in postmenopausal women with breast cancer treated with raloxifene. Int Semin Surg Oncol 4:18
41. Cakmak A, Posaci C, Dogan E, Caliskan S, Guclu S, Altunyurt S (2005) Raloxifene increases serum leptin levels in postmenopausal women: a prospective study. Am J Obstet Gynecol 193(2):347-351 (Pubitemid 41159525)
42. Balogh A, Kauf E, Vollanth R, Graser G, Klinger G, Oettel M (2000) Effects of two oral contraceptives on plasma levels of insulin-like growth factor I (IGF-I) and growth hormone (hGH). Contraception 62(5):259-269 (Pubitemid 32126660)
43. Gibney J, Johannsson G, Leung KC, Ho KK (2005) Comparison of the metabolic effects of raloxifene and oral estrogen in postmenopausal and growth hormone-deficient women. J Clin Endocrinol Metab 90(7):3897-3903 (Pubitemid 41058148)
44. Stamatakis E, Weiler R, Ioannidis JP (2013) Undue industry influences that distort healthcare research, strategy, expenditure and practice: a review. Eur J Clin Invest 43(5):469-475
45. Waffenschmidt S, Janzen T, Hausner E, Kaiser T (2013) Simple search techniques inPubMed are potentially suitable for evaluating the completeness of systematic reviews. J Clin Epidemiol 66(6):660-665
46. Doi SA, Thalib L (2008) A quality-effects model for metaanalysis. Epidemiology 19(1):94-100
47. Clemmons DR (2011) Consensus statement on the standardization and evaluation of growth hormone and insulin-like growth factor assays. Clin Chem 57(4):555-559
48. Doi SA, Barendregt JJ, Mozurkewich EL (2011) Meta-analysis of heterogeneous clinical trials: an empirical example. Contemp Clin Trials 32(2):288-298
49. Higgins JP, Deeks JJ (2008) Chapter 7: Selecting studies and collecting data. In: Higgins J, Green S (eds.) Cochrane Handbook for Systematic Reviews of Interventions V5.0.1 [updated Sept 2008]. The Cochrane Collaboration
50. Takkouche B, Cadarso-Suarez C, Spiegelman D (1999) Evaluation of old and new tests of heterogeneity in epidemiologic metaanalysis. Am J Epidemiol 150(2):206-215 (Pubitemid 29340156)
51. Onitilo AA, Doi SAR, Barendregt JJ (2013) Chapter 15: metaanalysis II Interpretation and use of outputs. In: Doi SA, Williams GM (eds) Methods Clin Epidemiol. Springer-Verlag, Berlin, pp 253-266
52. Suikkari AM, Tiitinen A, Stenman UH, Seppala M, Laatikainen T (1991) Oral contraceptives increase insulin-like growth factor binding protein-1 concentration in women with polycystic ovarian disease. Fertil Steril 55(5):895-899
53. Duursma SA, Bijlsma JW, Van Paassen HC, van Buul-Offers SC, Skottner-Lundin A (1984) Changes in serum somatomedin and growth hormone concentrations after 3 weeks oestrogen substitution in post-menopausal women; a pilot study. Acta Endocrinol (Copenh) 106(4):527-531 (Pubitemid 14053027)
54. Dawson-Hughes B, Stern D, Goldman J, Reichlin S (1986) Regulation of growth hormone and somatomedin-C secretion in postmenopausal women: effect of physiological estrogen replacement. J Clin Endocrinol Metab 63(2):424-432 (Pubitemid 16035693)
55. Bellantoni MF, Vittone J, Campfield AT, Bass KM, Harman SM, Blackman MR (1996) Effects of oral versus transdermal estrogen on the growth hormone/insulin-like growth factor I axis in younger and older postmenopausal women: a clinical research center study. J Clin Endocrinol Metab 81(8):2848-2853 (Pubitemid 26323876)
56. Leung KC, Johannsson G, Leong GM, Ho KK (2004) Estrogen regulation of growth hormone action. Endocr Rev 25(5):693-721 (Pubitemid 39366048)
57. Leung KC, Doyle N, Ballesteros M, Sjogren K,Watts CK, Low TH, Leong GM, Ross RJ, Ho KK (2003) Estrogen inhibits GH signaling by suppressing GH-induced JAK2 phosphorylation, an effect mediated by SOCS-2. Proc Natl Acad Sci USA 100(3):1016-1021 (Pubitemid 36183947)
58. Friend KE, Hartman ML, Pezzoli SS, Clasey JL, Thorner MO (1996) Both oral and transdermal estrogen increase growth hormone release in postmenopausal women-a clinical research center study. J Clin Endocrinol Metab 81(6):2250-2256 (Pubitemid 26176712)
59. Helle SI, Omsjo IH, Hughes SC, Botta L, Huls G, Holly JM, Lonning PE (1996) Effects of oral and transdermal oestrogen replacement therapy on plasma levels of insulin-like growth factors and IGF binding proteins 1 and 3: a cross-over study. Clin Endocrinol (Oxf) 45(6):727-732 (Pubitemid 27032319)
60. Birzniece V, Ho KK (2012) Growth and development: patching up a better pill for GH-deficient women. Nat Rev. Endocrinol 8(4):197-198
61. Riggs BL, Hartmann LC (2003) Selective estrogen-receptor modulators-mechanisms of action and application to clinical practice. N Engl J Med 348(7):618-629 (Pubitemid 36210865)
62. Gibney J, Wolthers T, Johannsson G, Umpleby AM, Ho KK (2005) Growth hormone and testosterone interact positively to enhance protein and energy metabolism in hypopituitary men. Am J Physiol Endocrinol Metab 289(2):E266-E271 (Pubitemid 41076627)
63. Nugent AG, Leung KC, Sullivan D, Reutens AT, Ho KK (2003) Modulation by progestogens of the effects of oestrogen on hepatic endocrine function in postmenopausal women. Clin Endocrinol (Oxf) 59(6):690-698 (Pubitemid 37491572)
64. Heald A, Selby PL, White A, Gibson JM (2000) Progestins abrogate estrogen-induced changes in the insulin-like growth factor axis. Am J Obstet Gynecol 183(3):593-600
65. Campagnoli C, Biglia N, Lanza MG, Lesca L, Peris C, Sismondi P (1994) Androgenic progestogens oppose the decrease of insulinlike growth factor I serum level induced by conjugated oestrogens in postmenopausal women. Prelim Rep. Maturitas 19(1):25-31 (Pubitemid 24192444)
66. Schreiber I, Buchfelder M, Droste M, Forssmann K, Mann K, Saller B, Strasburger CJ (2007) Treatment of acromegaly with the GH receptor antagonist pegvisomant in clinical practice: safety and efficacy evaluation from the German pegvisomant observational study. Eur J Endocrinol 156(1):75-82 (Pubitemid 46553905)
67. Grynberg M, Salenave S, Young J, Chanson P (2010) Female gonadal function before and after treatment of acromegaly. J Clin Endocrinol Metabol 95(10):4518-4525
68. Landin-Wilhelmsen K, Tengborn L, Wilhelmsen L, Bengtsson BA (1997) Elevated fibrinogen levels decrease following treatment of acromegaly. Clin Endocrinol (Oxf) 46(1):69-74 (Pubitemid 27072848)
69. Schwartz E, Echemendia E, Schiffer M, Panariello VA (1969) Mechanism of estrogenic action in acromegaly. J Clin Invest 48(2):260-270
70. Bijlsma JW, Duursma SA (1986) Serum concentrations of somatomedins and growth hormone in relation to bone metabolism in acromegaly and thyroid dysfunction. Clin Exp Rheumatol 4(2):105-110 (Pubitemid 16056594)
71. Deller JJ Jr, Di Raimondo VC, Grodsky GM, Forsham PH (1966) Acromegaly. The effects of various steroid hormones on the insulin-induced growth hormone response. Calif Med 104(1):1-5
72. Ho KK, Valiontis E, Waters MJ, Rajkovic IA (1993) Regulation of growth hormone binding protein in man: comparison of gel chromatography and immunoprecipitation methods. J Clin Endocrinol Metab 76(2):302-308 (Pubitemid 23073046)